WO2003064606A3 - Human monoclonal antibodies to prostate specific membrane antigen (psma) - Google Patents

Human monoclonal antibodies to prostate specific membrane antigen (psma) Download PDF

Info

Publication number
WO2003064606A3
WO2003064606A3 PCT/US2003/002448 US0302448W WO03064606A3 WO 2003064606 A3 WO2003064606 A3 WO 2003064606A3 US 0302448 W US0302448 W US 0302448W WO 03064606 A3 WO03064606 A3 WO 03064606A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
psma
human monoclonal
prostate specific
specific membrane
Prior art date
Application number
PCT/US2003/002448
Other languages
French (fr)
Other versions
WO2003064606A2 (en
Inventor
Yashwant M Deo
Robert Graziano
Debra Hudson
Eric H Holmes
William T Tino
Amelia Black
Original Assignee
Medarex Inc
Yashwant M Deo
Robert Graziano
Debra Hudson
Eric H Holmes
William T Tino
Amelia Black
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc, Yashwant M Deo, Robert Graziano, Debra Hudson, Eric H Holmes, William T Tino, Amelia Black filed Critical Medarex Inc
Priority to NZ534687A priority Critical patent/NZ534687A/en
Priority to JP2003564202A priority patent/JP2005518789A/en
Priority to CA002474616A priority patent/CA2474616A1/en
Priority to EP03721280A priority patent/EP1519747A4/en
Priority to AU2003224604A priority patent/AU2003224604B2/en
Priority to KR10-2004-7011643A priority patent/KR20040077889A/en
Priority to BR0307216-9A priority patent/BR0307216A/en
Priority to MXPA04007262A priority patent/MXPA04007262A/en
Publication of WO2003064606A2 publication Critical patent/WO2003064606A2/en
Publication of WO2003064606A3 publication Critical patent/WO2003064606A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Abstract

Isolated human monoclonal antibodies which bind to PSMA, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
PCT/US2003/002448 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (psma) WO2003064606A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
NZ534687A NZ534687A (en) 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (PSMA) seq id 54
JP2003564202A JP2005518789A (en) 2002-01-28 2003-01-28 Human monoclonal antibody against prostate specific membrane antigen (PSMA)
CA002474616A CA2474616A1 (en) 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (psma)
EP03721280A EP1519747A4 (en) 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (psma)
AU2003224604A AU2003224604B2 (en) 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
KR10-2004-7011643A KR20040077889A (en) 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (psma)
BR0307216-9A BR0307216A (en) 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (psma)
MXPA04007262A MXPA04007262A (en) 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (psma).

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5998902A 2002-01-28 2002-01-28
US10/059,989 2002-01-28

Publications (2)

Publication Number Publication Date
WO2003064606A2 WO2003064606A2 (en) 2003-08-07
WO2003064606A3 true WO2003064606A3 (en) 2005-02-03

Family

ID=27658271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/002448 WO2003064606A2 (en) 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (psma)

Country Status (10)

Country Link
EP (1) EP1519747A4 (en)
JP (1) JP2005518789A (en)
KR (1) KR20040077889A (en)
CN (1) CN1652821A (en)
AU (1) AU2003224604B2 (en)
BR (1) BR0307216A (en)
CA (1) CA2474616A1 (en)
MX (1) MXPA04007262A (en)
NZ (1) NZ534687A (en)
WO (1) WO2003064606A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43586E1 (en) 1992-11-05 2012-08-14 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
CA2464239C (en) 2001-10-23 2016-07-12 Psma Development Company, L.L.C. Psma antibodies and protein multimers
KR20060135690A (en) * 2003-12-10 2006-12-29 메다렉스, 인코포레이티드 Ip-10 antibodies and their uses
US7625559B2 (en) * 2004-02-06 2009-12-01 University Of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
EP1735348B1 (en) * 2004-03-19 2012-06-20 Imclone LLC Human anti-epidermal growth factor receptor antibody
EP2357201B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
DK1836225T3 (en) 2005-01-06 2012-02-27 Innate Pharma Sas Kir-binding agents and methods for using them
EP1851250B1 (en) * 2005-02-18 2012-06-06 Medarex, Inc. Human monoclonal antibody to prostate specific membrane antigen (psma)
MX2007009935A (en) * 2005-02-18 2007-10-10 Medarex Inc Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues.
CA2607147C (en) * 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
AU2007226542B2 (en) * 2006-03-14 2013-08-22 Cancer Targeted Technology Llc Peptidomimetic inhibitors of PSMA,compounds comprising them, and methods of use
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
PL2326350T3 (en) 2008-09-08 2014-03-31 Psma Dev Company L L C Compounds for killing psma-expressing, taxane-resistant cancer cells
DK2356153T3 (en) * 2008-10-01 2016-07-04 Amgen Res (Munich) Gmbh Bispecific single CHAIN ​​PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
CN101891818B (en) * 2009-01-16 2012-07-25 中国人民解放军第四军医大学 Single-chain antibody in anti-human prostate-specific membrane antigen extracellular region and application thereof
CA2758751C (en) * 2009-04-14 2017-03-21 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
MX355908B (en) 2011-04-22 2018-05-04 Aptevo Res & Development Llc Prostate-specific membrane antigen binding proteins and related compositions and methods.
CN104837502B (en) 2012-10-12 2018-08-10 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
ES2687439T3 (en) 2013-03-13 2018-10-25 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN103333249A (en) * 2013-06-14 2013-10-02 广州康合生物科技有限公司 PSMA (Prostate Specific Membrane Antigen) monoclonal antibody and applications thereof
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AR104484A1 (en) * 2015-03-10 2017-07-26 Sorrento Therapeutics Inc ANTI-PSMA ANTIBODIES AS THERAPEUTIC AGENTS
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
UA126278C2 (en) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Cd3 binding polypeptides
KR101704379B1 (en) * 2015-10-27 2017-02-08 (주)알테오젠 Antibody-Drug Conjugate and Method of Producing the Same
WO2017164678A2 (en) 2016-03-23 2017-09-28 서울대학교산학협력단 Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same
CA3024723A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
CN116987189A (en) 2016-05-20 2023-11-03 哈普恩治疗公司 Single chain variable fragment CD3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
BR112019010602A2 (en) 2016-11-23 2019-12-17 Harpoon Therapeutics Inc trispecific psma proteins and methods of use
EA201991168A1 (en) 2016-11-23 2019-12-30 Харпун Терапьютикс, Инк. PROTEIN BINDING PROSTATIC SPECIFIC MEMBRANE ANTIGEN
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
CN113896792A (en) 2017-05-12 2022-01-07 哈普恩治疗公司 Mesothelin binding proteins
MX2020003856A (en) 2017-10-13 2020-08-13 Harpoon Therapeutics Inc B cell maturation antigen binding proteins.
AU2018347582A1 (en) 2017-10-13 2020-05-07 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
JP7425049B2 (en) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． DLL3 binding protein and method of use
CN113226472A (en) 2018-12-17 2021-08-06 雷维托普有限公司 Dual immune cell adaptor
TW202132353A (en) * 2020-02-18 2021-09-01 大陸商和鉑醫藥（上海）有限責任公司 An isolated antigen psma binding protein and the use thereof
KR20220144841A (en) 2020-02-21 2022-10-27 하푼 테라퓨틱스, 인크. FLT3 Binding Proteins and Methods of Use
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US20230201366A1 (en) 2021-11-19 2023-06-29 Adc Therapeutics Sa Anti-psma conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2155854T3 (en) * 1993-06-09 2001-06-01 Unilever Nv PROCESS OF PRODUCTION OF FUSION PROTEINS THAT INCLUDES SCFV FRAGMENTS WITH THE HELP OF A TRANSFORMED MOLD.
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
IL147638A0 (en) * 1999-07-29 2002-08-14 Medarex Inc Human monoclonal antibodies to prostate specific membrane antigen
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
PT2281843T (en) * 2000-06-16 2017-01-02 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
CA2464239C (en) * 2001-10-23 2016-07-12 Psma Development Company, L.L.C. Psma antibodies and protein multimers
AU2003270010A1 (en) * 2002-08-30 2004-03-19 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
JP2006517188A (en) * 2002-12-02 2006-07-20 アブジェニックス・インコーポレーテッド Antibody against phospholipase A2 and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GONG M.C. ET AL.: "Prostate-specific membrane antigen (PMSA)-specific monoclonal antibodies in the treatment of prostate and other cancers", CANCER METASTASIS REV., vol. 18, no. 4, 1999, pages 483 - 490, XP002982445 *
GREEN L.L. ET AL.: "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies", J. IMMUNOL. METHODS, vol. 231, 1999, pages 11 - 23, XP004187631 *
See also references of EP1519747A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43586E1 (en) 1992-11-05 2012-08-14 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen

Also Published As

Publication number Publication date
MXPA04007262A (en) 2004-10-29
BR0307216A (en) 2005-12-20
CA2474616A1 (en) 2003-08-07
EP1519747A2 (en) 2005-04-06
KR20040077889A (en) 2004-09-07
NZ534687A (en) 2007-10-26
JP2005518789A (en) 2005-06-30
AU2003224604B2 (en) 2007-06-14
WO2003064606A2 (en) 2003-08-07
CN1652821A (en) 2005-08-10
EP1519747A4 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
LTPA2021514I1 (en)
HK1049015A1 (en) Human monoclonal antibodies to prostate specific membrane antigen
WO2004076620A3 (en) Human antibodies specific for interleukin 15 (il-15)
AU2003303237A1 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
WO2002100348A8 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
WO2003017935A3 (en) Human antibodies specific for interleukin 15 (il-15)
WO2004043989A3 (en) Human monoclonal antibodies to heparanase
WO2003040169A3 (en) Human monoclonal antibodies to dendritic cells
WO2001009187A3 (en) Human monoclonal antibodies to her2/neu
WO2004045512A3 (en) Human monoclonal antibodies against cd25
WO2003059282A3 (en) Human monoclonal antibodies against cd30
WO2001085798A3 (en) Human monoclonal antibodies to dendritic cells
RS20050724A (en) Human antibodies specific for interleukin 15(il-15)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 163115

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003564202

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2474616

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007262

Country of ref document: MX

Ref document number: 1020047011643

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003224604

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200406455

Country of ref document: ZA

Ref document number: 534687

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003721280

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1908/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 20038073714

Country of ref document: CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003721280

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0307216

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2003721280

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003224604

Country of ref document: AU